Descriptive analysis of Cycle Threshold in patients with hematologic malignancies infected with SARS-COV-2

Authors

  • Ignacio Martín Santarelli Universidad de Buenos Aires, Facultad de Medicina, Hospital de Clínicas “José de San Martín”, Departamento de Medicina.
  • Diego Jorge Manzella Universidad de Buenos Aires, Facultad de Medicina
  • Lucía Gallo Vaulet Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Cátedra de Microbiología Clínica. Universidad de Buenos Aires, Instituto de Fisiopatología y Bioquímica Clínica.
  • Marcelo Rodríguez Fermepín Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Cátedra de Microbiología Clínica. Universidad de Buenos Aires, Instituto de Fisiopatología y Bioquímica Clínica.
  • Sofía Isabel Fernández Universidad de Buenos Aires, Facultad de Medicina, Hospital de Clínicas “José de San Martín”, Departamento de Medicina.

DOI:

https://doi.org/10.31053/1853.0605.v80.n1.38171

Keywords:

polymerase chain reaction, hematologic neoplasms, coronavirus infections

Abstract

Introduction: SARS-CoV-2 has caused over 200 million documented infections, more than 4 million deaths, and unprecedented consequences worldwide. The cycle threshold (Ct), the number of amplification cycles required to obtain a product detectable through fluorescence during a quantitative RT-PCR test, is an indirect measurement of viral load. Patients with hematologic malignancies have an increased risk of death by the SARS-CoV-2. Cases presentation: We conducted a retrospective, observational, descriptive analysis of the Ct obtained from patients with history of hematologic malignancies who tested positive for SARS-CoV-2 in our hospital, from March 3rd, 2020, to August 17th, 2021. We used the mean Ct at diagnosis. 15 adults, with previous diagnosis of lymphomas, acute leukemias and chronic lymphocytic leukemia, were included. 9 of the 15 patients (60 %) developed pneumonia, 6 of them required supplementary oxygen and 5 mechanical ventilation. 5 patients died between 7-86 days from symptom onset. Ct was lower among the group of patients who died (15.5 cycles; SD= 2.28, CI95%= 9.17-21.86) compared with those who survived (20.2 cycles; SD= 8.87, CI95%= 13.9-26.6). Ct was also lower in the pneumonia group (18.2 cycles; SD= 2.28, CI95%= 12.98-23.51) than in the no-pneumonia group (19.3 cycles; SD= 4.11; CI95%= 8.73-29.9). Discussion: Ct was lowest in severe forms of CoViD-19. Further studies with larger populations of patients with hematologic malignancies could establish the validity of Ct as a quantitative laboratory determination as a course-prediction and infectivity tool.

Downloads

Download data is not yet available.

Author Biographies

Ignacio Martín Santarelli, Universidad de Buenos Aires, Facultad de Medicina, Hospital de Clínicas “José de San Martín”, Departamento de Medicina.

Universidad de Buenos Aires, Facultad de Medicina, Hospital de Clínicas “José de San Martín”, Departamento de Medicina.

Diego Jorge Manzella, Universidad de Buenos Aires, Facultad de Medicina

Universidad de Buenos Aires, Facultad de Medicina

Lucía Gallo Vaulet, Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Cátedra de Microbiología Clínica. Universidad de Buenos Aires, Instituto de Fisiopatología y Bioquímica Clínica.

Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Cátedra de Microbiología Clínica. Universidad de Buenos Aires, Instituto de Fisiopatología y Bioquímica Clínica.

Marcelo Rodríguez Fermepín, Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Cátedra de Microbiología Clínica. Universidad de Buenos Aires, Instituto de Fisiopatología y Bioquímica Clínica.

Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Cátedra de Microbiología Clínica. Universidad de Buenos Aires, Instituto de Fisiopatología y Bioquímica Clínica.

Sofía Isabel Fernández, Universidad de Buenos Aires, Facultad de Medicina, Hospital de Clínicas “José de San Martín”, Departamento de Medicina.

Universidad de Buenos Aires, Facultad de Medicina, Hospital de Clínicas “José de San Martín”, Departamento de Medicina.

References

World Health Organization [Internet]. WHO Coronavirus (COVID-19) Dashboard [cited 2021 Aug 29]. Available from: https://covid19.who.int/

Wood WA, Neuberg DS, Thompson JC, Tallman MS, Sekeres MA, Sehn LH, Anderson KC, Goldberg AD, Pennell NA, Niemeyer CM, Tucker E, Hewitt K, Plovnick RM, Hicks LK. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv. 2020 Dec 8;4(23):5966-5975. doi: 10.1182/bloodadvances.2020003170.

Basquiera AL, García MJ, Martinez Rolón J, Olmedo J, Laviano J, Burgos R, Caeiro G, Remaggi G, Raña P, Paoletti M, González CM, Fernández I, Pavlovsky A, Perusini MA, Rodriguez A, Guanchiale L, Carvani A, Mandrile L, Figueroa F, Vicente Reparaz A, Fragapane Mathus PN, Garate G, Fauque ME, Kantor G, Cruset S, Gonzalez Lorch JS, Szelagowski M, Giarini MP, Oliveira N, García MC, Ventriglia MV, Pereyra PH, Gutierrez DR, Kusminsky G, Troccoli J, Freitas MJ, Cranco S, Del V Sanchez N, Rey I, Funes ME, Jarchum S, Freue J, Miroli A, Guerrero O, López Ares L, Campestri R, Bove V, Salinas GN, Cabrejo M, Milone JH, Zabaljauregui S, Gotta D, Dupont JC, Stemmelin G. Clinical characteristics and evolution of hematological patients and COVID-19 in Argentina: a report from the Argentine Society of Hematology. Medicina (B Aires). 2021;81(4):536-545. English.

World Health Organization [Internet]. WHO Coronavirus (COVID-19) Dashboard [cited 2021 Oct 12]. Available from: https://covid19.who.int/

Oh MD, Park WB, Choe PG, Choi SJ, Kim JI, Chae J, Park SS, Kim EC, Oh HS, Kim EJ, Nam EY, Na SH, Kim DK, Lee SM, Song KH, Bang JH, Kim ES, Kim HB, Park SW, Kim NJ. Viral Load Kinetics of MERS Coronavirus Infection. N Engl J Med. 2016 Sep 29;375(13):1303-5. doi: 10.1056/NEJMc1511695.

Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, Law KI, Tang BS, Hon TY, Chan CS, Chan KH, Ng JS, Zheng BJ, Ng WL, Lai RW, Guan Y, Yuen KY; HKU/UCH SARS Study Group. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003 May 24;361(9371):1767-72. doi: 10.1016/s0140-6736(03)13412-5.

Tang YW, Schmitz JE, Persing DH, Stratton CW. Laboratory Diagnosis of COVID-19: Current Issues and Challenges. J Clin Microbiol. 2020 May 26;58(6):e00512-20. doi: 10.1128/JCM.00512-20

Engelmann I, Alidjinou EK, Ogiez J, Pagneux Q, Miloudi S, Benhalima I, Ouafi M, Sane F, Hober D, Roussel A, Cambillau C, Devos D, Boukherroub R, Szunerits S. Preanalytical Issues and Cycle Threshold Values in SARS-CoV-2 Real-Time RT-PCR Testing: Should Test Results Include These? ACS Omega. 2021 Mar 6;6(10):6528-6536. doi: 10.1021/acsomega.1c00166.

Westblade LF, Brar G, Pinheiro LC, Paidoussis D, Rajan M, Martin P, Goyal P, Sepulveda JL, Zhang L, George G, Liu D, Whittier S, Plate M, Small CB, Rand JH, Cushing MM, Walsh TJ, Cooke J, Safford MM, Loda M, Satlin MJ. SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19. Cancer Cell. 2020 Nov 9;38(5):661-671.e2. doi: 10.1016/j.ccell.2020.09.007.

Trunfio M, Venuti F, Alladio F, Longo BM, Burdino E, Cerutti F, Ghisetti V, Bertucci R, Picco C, Bonora S, Di Perri G, Calcagno A. Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients. Viruses. 2021 Feb 11;13(2):281. doi: 10.3390/v13020281.

Infectious Disease Society of America [Internet]. IDSA and AMP joint statement on the use of SARS-CoV-2 PCR cycle threshold (Ct) values for clinical decision-making [cited 2021 Oct 12]. Available from: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwjdks33rtz9AhWLA7kGHQh5CDoQFnoECA0QAQ&url=https%3A%2F%2Fwww.idsociety.org%2Fglobalassets%2Fidsa%2Fpublic-health%2Fcovid-19%2Fidsa-amp-statement.pdf&usg=AOvVaw0d7f3_epqIq1ogkyAkb1oI

Freire-Paspuel B, Garcia-Bereguiain MA. Analytical sensitivity and clinical performance of a triplex RT-qPCR assay using CDC N1, N2, and RP targets for SARS-CoV-2 diagnosis. Int J Infect Dis 2021; 102:14-16.

Ludueña MG, Labato M, Chiaradia V, Yamuni J, Finocchietto P, Pisarevsky AA. Análisis de los primeros 100 pacientes internados por COVID-19 en el Hospital de Clínicas José de San Martín, Universidad de Buenos Aires [Analysis of the first 100 patients with COVID-19 admitted to internal medicine wards at the Hospital de Clínicas José de San Martin, Buenos Aires University]. Medicina (B Aires). 2020;80 Suppl 6:48-55. Spanish.

La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, Gautret P, Raoult D. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1059-1061. doi: 10.1007/s10096-020-03913-9.

Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, Solomon IH, Kuo HH, Boucau J, Bowman K, Adhikari UD, Winkler ML, Mueller AA, Hsu TY, Desjardins M, Baden LR, Chan BT, Walker BD, Lichterfeld M, Brigl M, Kwon DS, Kanjilal S, Richardson ET, Jonsson AH, Alter G, Barczak AK, Hanage WP, Yu XG, Gaiha GD, Seaman MS, Cernadas M, Li JZ. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med. 2020 Dec 3;383(23):2291-2293. doi: 10.1056/NEJMc2031364.

Downloads

Published

2023-03-31

How to Cite

1.
Santarelli IM, Manzella DJ, Gallo Vaulet L, Rodríguez Fermepín M, Fernández SI. Descriptive analysis of Cycle Threshold in patients with hematologic malignancies infected with SARS-COV-2. Rev Fac Cien Med Univ Nac Cordoba [Internet]. 2023 Mar. 31 [cited 2024 Jul. 4];80(1):47-51. Available from: https://revistas.unc.edu.ar/index.php/med/article/view/38171

Issue

Section

Case Report